278 related articles for article (PubMed ID: 17344244)
1. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study.
Nacci F; Righi A; Conforti ML; Miniati I; Fiori G; Martinovic D; Melchiorre D; Sapir T; Blank M; Shoenfeld Y; Pignone AM; Cerinic MM
Ann Rheum Dis; 2007 Jul; 66(7):977-9. PubMed ID: 17344244
[TBL] [Abstract][Full Text] [Related]
2. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.
Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin R; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold J
Arthritis Rheum; 1999 Nov; 42(11):2372-80. PubMed ID: 10555033
[TBL] [Abstract][Full Text] [Related]
3. Mandibular function is severely impaired in systemic sclerosis patients.
Ferreira EL; Christmann RB; Borba EF; Borges CT; Siqueira JT; Bonfa E
J Orofac Pain; 2010; 24(2):197-202. PubMed ID: 20401358
[TBL] [Abstract][Full Text] [Related]
4. A longitudinal follow-up of hand involvement and activities of daily living in early systemic sclerosis.
Sandqvist G; Hesselstrand R; Eberhardt K
Scand J Rheumatol; 2009; 38(4):304-10. PubMed ID: 19296402
[TBL] [Abstract][Full Text] [Related]
5. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases.
Johnson SR; Glaman DD; Schentag CT; Lee P
J Rheumatol; 2006 Jun; 33(6):1117-22. PubMed ID: 16622903
[TBL] [Abstract][Full Text] [Related]
6. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Seibold JR
Arthritis Rheum; 2001 Mar; 44(3):653-61. PubMed ID: 11263780
[TBL] [Abstract][Full Text] [Related]
7. A three-year follow-up study of the development of joint contractures in 131 patients with systemic sclerosis.
Bálint Z; Farkas H; Farkas N; Minier T; Kumánovics G; Horváth K; Solyom AI; Czirják L; Varjú C
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-68-74. PubMed ID: 25152080
[TBL] [Abstract][Full Text] [Related]
8. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
Khanna D; Furst DE; Clements PJ; Park GS; Hays RD; Yoon J; Korn JH; Merkel PA; Rothfield N; Wigley FM; Moreland LW; Silver R; Steen VD; Weisman M; Mayes MD; Collier DH; Medsger TA; Seibold JR; ;
J Rheumatol; 2005 May; 32(5):832-40. PubMed ID: 15868618
[TBL] [Abstract][Full Text] [Related]
9. Psychometric properties of the Swedish version of the Scleroderma Health Assessment Questionnaire and the Cochin Hand Function Scale in patients with systemic sclerosis.
Hesselstrand R; Nilsson JÅ; Sandqvist G
Scand J Rheumatol; 2013; 42(4):317-24. PubMed ID: 23442162
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience.
Agostini E; De Luca G; Bruni C; Bartoli F; Tofani L; Campochiaro C; Pacini G; Moggi-Pignone A; Guiducci S; Bellando-Randone S; Shoenfeld Y; Dagna L; Matucci-Cerinic M
Autoimmun Rev; 2021 Dec; 20(12):102981. PubMed ID: 34718166
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of self-administered stretching for finger joint motion in Japanese patients with systemic sclerosis.
Mugii N; Hasegawa M; Matsushita T; Kondo M; Orito H; Yanaba K; Komura K; Hayakawa I; Hamaguchi Y; Ikuta M; Tachino K; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2006 Aug; 33(8):1586-92. PubMed ID: 16881115
[TBL] [Abstract][Full Text] [Related]
12. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease.
Valentini G; Paone C; La Montagna G; Chiarolanza I; Menegozzo M; Colutta E; Ruocco L
Scand J Rheumatol; 2006; 35(1):35-8. PubMed ID: 16467039
[TBL] [Abstract][Full Text] [Related]
13. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
Clements PJ; Hurwitz EL; Wong WK; Seibold JR; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Furst DE
Arthritis Rheum; 2000 Nov; 43(11):2445-54. PubMed ID: 11083267
[TBL] [Abstract][Full Text] [Related]
14. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
[TBL] [Abstract][Full Text] [Related]
15. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
16. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
17. The evaluation of a home-based program for hands in patients with systemic sclerosis.
Landim SF; Bertolo MB; Marcatto de Abreu MF; Del Rio AP; Mazon CC; Marques-Neto JF; Poole JL; de Paiva Magalhães E
J Hand Ther; 2019; 32(3):313-321. PubMed ID: 29198478
[TBL] [Abstract][Full Text] [Related]
18. The Belgian Systemic Sclerosis Cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile.
Vanthuyne M; Smith V; De Langhe E; Van Praet J; Arat S; Depresseux G; Westhovens R; Blockmans D; Badot V; Cogan E; De Keyser F; Houssiau FA
J Rheumatol; 2012 Nov; 39(11):2127-33. PubMed ID: 22984273
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of functional disability using the health assessment questionnaire in Japanese patients with systemic sclerosis.
Kuwana M; Sato S; Kikuchi K; Kawaguchi Y; Fujisaku A; Misaki Y; Hatamochi A; Kondo H; Takehara K
J Rheumatol; 2003 Jun; 30(6):1253-8. PubMed ID: 12784399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
